Form 4: Intellia Therapeutics EVP, Chief Medical Officer Lebwohl Reports Stock and Option Transactions

David Lebwohl, EVP and Chief Medical Officer of Intellia Therapeutics, reports acquisition of restricted stock units and stock options.

Summary

• David Lebwohl, the EVP and Chief Medical Officer of Intellia Therapeutics, reported transactions involving the company's stock.
• On March 1, 2024, Lebwohl acquired 38,701 shares of common stock through restricted stock units at a price of $0.
• Following this transaction, Lebwohl beneficially owns 93,073 shares of Intellia common stock.
• Additionally, on March 1, 2024, Lebwohl acquired options to purchase 55,855 shares of common stock at an exercise price of $32.66, expiring on February 28, 2034.
• The options vest with 33% on January 1, 2025, and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of restricted stock units and stock options by a key executive could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions reported may influence investor perception of the company.

Key Dates